Company intelligence / Profile preview

Suzhou Stainwei Biotechnology Co., Ltd.

Suzhou, Jiangsu Sheng, Chinastainwei.cn ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has multiple programs in development, with the highest being Phase 2 trials. Their anti-VEGF monoclonal antibody has shown positive results in Phase 1 trials with no dose-limiting toxicities observed. They also have an anti-PD-1 humanized monoclonal antibody (hAB21) that has completed Phase 1 trials for advanced malignant solid tumors.

Therapeutic areas: OncologyEndocrinologyImmunologyHematologyOphthalmologyNeurologyInfectious Diseases
Modalities: Monoclonal antibodySmall molecule drugRecombinant geneProtein engineering
Industry: Biotech

Drug pipeline

3 assets

ARMOZX

Unknown

2 more assets in the full pipeline.

Request access →

Partnerships

Maimonides Medical Center

Beyond the preview

Go deeper on Suzhou Stainwei Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Stainwei Biotechnology Co., Ltd..

Explore the full profile